Impact of proton pump inhibitors on pathologic response rates following fluoropyrimidine-based neoadjuvant chemotherapy in pancreatic cancer patients.
Jessica A SteadmanAhmer SultanCourtney N DayMarie A ParishSusanne G WarnerMichael L KendrickMark J TrutyZhaohui JinCornelius A ThielsPublished in: Journal of surgical oncology (2024)
PPI usage did not significantly influence mPR or OS following neoadjuvant fluoropyrimidine-based chemotherapy in resected PDAC patients. Further analysis of all patients, not just those who underwent resection, is required.